Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gilead Sciences Inc GILD

Healthcare Biotechnology
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products... see more

Recent & Breaking News (NDAQ:GILD)

Québec Provides Access to Biktarvy® for the Treatment of HIV

Canada NewsWire August 15, 2019

China National Medical Products Administration Approves Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection

Business Wire August 9, 2019

Gilead Sciences Statement on U.S. Food and Drug Administration Advisory Committee's Recommendation on Descovy for PrEP(TM)

Business Wire August 7, 2019

Ontario Provides Access to Biktarvy® for the Treatment of HIV

Business Wire August 6, 2019

Ontario Provides Access to Biktarvy® for the Treatment of HIV

Canada NewsWire August 6, 2019

Gilead Sciences Announces Third Quarter 2019 Dividend

Business Wire July 30, 2019

Gilead Sciences Announces Second Quarter 2019 Financial Results

Business Wire July 30, 2019

Gilead Announces Latest Data in Ongoing HIV Cure Research Program

Business Wire July 23, 2019

Gilead Presents New Findings on Profile of Descovy® for Potential Use as HIV Pre-exposure Prophylaxis Compared With Truvada®

Business Wire July 23, 2019

Gilead Presents New Data on Biktarvy® for the Treatment of HIV in Women and in Virologically Suppressed Patients With Known Resistance

Business Wire July 22, 2019

Gilead Presents Proof-of-Concept Data for GS-6207, a First-in-Class Capsid Inhibitor, in People Living With HIV

Business Wire July 22, 2019

Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis

Business Wire July 19, 2019

Gilead to Present New Data on HIV Prevention, Treatment and Cure Research at IAS 2019

Business Wire July 18, 2019

Gilead Sciences' Chief Scientific Officer John McHutchison to Leave the Company

Business Wire July 17, 2019

Gilead Sciences Announces Changes to Senior Leadership Team

Business Wire July 17, 2019

Gilead Sciences to Release Second Quarter 2019 Financial Results on Tuesday, July 30, 2019

Business Wire July 16, 2019

Kite Announces Plans to Bolster Industry-Leading Cell Therapy Manufacturing Capabilities With New Viral Vector Facility

Business Wire July 16, 2019

Gilead and Galapagos Enter Into Transformative Research and Development Collaboration

Business Wire July 14, 2019

Gilead Appoints Christi L. Shaw as Chief Executive Officer of Kite

Business Wire July 11, 2019

Gilead Sciences and Renown Institute for Health Innovation Announce Strategic Collaboration to Advance Understanding of Nonalcoholic Steatohepatitis (NASH)

Business Wire July 11, 2019